Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Boston Scientific (BSX) Any Comments??? -- Ignore unavailable to you. Want to Upgrade?

To: OldAIMGuy who wrote (761)	3/26/2001 9:25:35 AM
From: Lighthouse	Read Replies (1) \| Respond to of 798

Maybe. (What a whimmpy answer) I suspect the ability to move above $20 convincingly will rest with news out of the coated stent program. I have read some reports lately that might favor BSX's drug (in the stent) over JNJ's drug (in the stent). This is still way too early to call, but any preception of this will move the shares up. Finally something to look forward to. I still feel the coated stents will take market share rapidly from the non coated stents and command much higher prices. So far current leader GDT is behind BSX and JNJ. MDT is even farther behind IMHO. If BSX buys Medinol for more than $2B we may see the $13 per share range again. Just some thoughts. All the other divisions appear to be doing at least o.k. Cheers,